Mubadala commits to China with significant UCB Pharma partnership deal.

02 Sep, 2024

Mubadala commits to China with significant UCB Pharma partnership deal

Abu Dhabi's Mubadala has made a significant investment in the Asian market by acquiring a portion of UCB Pharma's China business, partnering with CBC Group. UCB, a Belgium-based biopharmaceutical company, holds a leading position in China’s immunology, neurology, and rare disease markets. This acquisition includes UCB's neurology and allergy portfolios, such as Keppra, Vimpat, Neupro, Zyrtec, and Xyzal, as well as the Zhuhai manufacturing site.

In 2023, these portfolios generated combined net sales of 131 million euros in China. The transaction, set to close in Q4 2024, aligns with Mubadala’s strategy to expand its presence in Asia, focusing on high-growth sectors like healthcare. This move is part of Mubadala's broader plan to establish platforms that address unmet needs in China and Asia’s healthcare markets.

The partnership with CBC Group builds on previous acquisitions like Hasten Biopharma, reinforcing Mubadala’s commitment to healthcare investments in the region. UCB plans to continue its focus on launching innovative medicines in immunology, neurology, and rare diseases in China, further enhancing patient outcomes through collaboration with local partners and fostering innovation.